SOHO 2024 | Which patients with ALL should be taken to transplant?
In this video, Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving role of stem cell transplant (SCT) in the treatment of acute lymphoblastic leukemia (ALL) , highlighting the impact of immunotherapies like CAR T-cells and antibodies. Dr Kebriaei emphasizes the importance of measurable residual disease (MRD) in guiding the decision to proceed with SCT, noting that access to MRD testing and novel therapies varies globally. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
